Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug safety “virtual” surveillance sought by FDA

Executive Summary

FDA will hold a public meeting to examine the feasibility of public-private partnerships to create a "virtual" product safety surveillance system based on existing datasets and collection activities. Topics will include the creation of "dynamic feedback loops" in which practitioners and patients fuel data collection and are provided with updated information after analysis. FDA is planning to devote user fee resources to overhaul its postmarketing surveillance efforts (1"The Pink Sheet" Jan. 15, 2007, p. 3). The meeting on the "Sentinel Network" will take place March 7-8 at the University System of Maryland Shady Grove Center in Rockville, Md...

You may also be interested in...



US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

Hikma Proves Resilient In 2020 Despite Some Bumpy Launches

Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.

AstraZeneca Cashes In Moderna Chips

The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel